«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2022年06期

页码:

776-781

栏目:

论著

出版日期:

2022-12-20

文章信息/Info

Title:

Prognostic analysis of adjuvant targeted therapy for EGFR-positive ⅠA stage invasive lung adenocarcinoma after complete resection

作者:

陈俞坊; 王康; 吴文昊; 张厚丽; 周向东

400038 重庆,陆军(第三)军医大学第一附属医院呼吸与危重症医学科

Author(s):

Chen Yufang;  Wang Kang;  Wu Wenhao;  Zhang Houli;  Zhou Xiangdong.

Department of Respiratory and Critical Care Medicin, Frist Affiliated Hospital, Army Military Medical University, Chongqing 400038, China

关键词:

ⅠA期;  浸润性肺腺癌;  肺小结节;  表皮生长因子受体酷氨酸激酶抑制剂;  表皮生长因子受体突变

Keywords:

Stage ⅠA;  Invasive lung adenocarcinoma;  Pulmonary nodules;  Epidermal growth factor receptor-tyrosine kinase inhibitor;  Epidermal growth factor receptor

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2022.06.002

摘要:

目的 分析ⅠA期浸润性肺腺癌切除术后EGFR敏感突变辅助性靶向治疗的疗效与安全性。方法 选择2016年1月至2022年2月我院收治的肺腺癌患者82例,采用倾向性得分匹配(PSM)分为观察组34例,对照组34例,观察组肿瘤复发、转移前行EGFR-TKIs治疗,允许术后化疗。对照组复发前未行EGFR-TKIs治疗或仅接受化疗。分析临床特征、术后治疗方案、疗效、中位无病生存期(DFS)及安全性。结果 观察组中位随访时间为22.43个月(8.57～56.39),对照组为22.16个月(7.14～51.00)。观察组复发3例(8.8%)、对照组复发10例(29.4%)。2年与3年DFS率观察组和对照组分别为97% vs. 71%、89% vs. 71%。观察组中位DFS未达到,对照组中位DFS为44.50个月(95%CI 24.51～64.49,P=0.014),HR=0.22(95%CI 0.06～0.81,P=0.023),术后EGFR-TKIs治疗复发风险降低78.0%。44.1%的患者出现靶向药物相关不良反应,主要的不良反应包括皮疹、肝功能异常,大部分患者可耐受。结论 EGFR敏感突变ⅠA期浸润性肺腺癌患者术后辅以EGFR-TKIs治疗能延长DFS,降低复发风险。

Abstract:

Objective To analyze the efficacy and safety of adjuvant targeted therapy for EGFR-positive stage ⅠA invasive lung adenocarcinoma after complete resection. Methods All of 82 patients with lung adenocarcinoma admitted in our hospital from January, 2016 to February, 2022 were selected and divided into observation group 34 cases and control group 34 cases by propensity score matching(PSM). The observation group was treated with EGFR-TKIs before tumor recurrence and metastasis, and postoperative chemotherapy was allowed.The control group was not treated with EGFR-TKIs or only received chemotherapy before recurrence. The clinical characteristics, postoperative treatment plan and efficacy, median disease-free survival(median DFS)and safety of the above patients were sorted and analyzed. Results After matching, the median follow-up time of observation group and control group were 22.43(8.57-56.39)months and 22.16(7.14-51.00)months. A total of 13 patients had endpoint events, including 3 patients(8.8%)in theobservation group and 10 patients(29.4%)in the control group. The 2-year DFS rate and 3-year DFS rate of the observation group and the control group were 97% vs. 71% and 89% vs. 71% respectively.The median DFS was undefined in the observation group. The median DFS of control groups was 44.50(24.51-64.49)months, P=0.014, HR=0.22(95%CI 0.06-0.81, P=0.023). 44.1% of the patients had targeted drugrelated adverse reactions, the main adverse reactions included rash and liver function, which were tolerable in most patients. Conclusion Postoperative EGFR-TKIs therapy can prolong the survival time and reduce the risk of recurrence in patients with EGFR-positive IA stage invasive lung adenocarcinoma.

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
3 Yotsukura M, Asamura H, Motoi N, et al. Long-term prognosis of patients with resected adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung[J]. J Thorac Oncol, 2021, 16(8): 1312-1320.
4 Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming(Eighth)edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51.
5 Yang Y, Mao Y, Yang L, et al. Prognostic factors in curatively resected pathological stage I lung adenocarcinoma[J]. J Thorac Dis, 2017, 9(12): 5267-5277.
6 Zhao W, Wang H, Xie J, et al. A clinicopathological study of small lung adenocarcinoma 1 cm or less in size: Emphasis on histological subtypes associated with lymph node metastasis and recurrence[J]. Int J Surg Pathol, 2018, 26(1): 4-11.
7 Neri S, Menju T, Sowa T, et al. Prognostic impact of microscopic vessel invasion and visceral pleural invasion and their correlations with epithelial-mesenchymal transition, cancer stemness, and treatment failure in lung adenocarcinoma[J]. Lung Cancer, 2019, 128: 13-19.
8 Chae M, Jeon JH, Chung JH, et al. Prognostic significance of tumor spread through air spaces in patients with stage ⅠA part-solid lung adenocarcinoma after sublobar resection[J]. Lung Cancer, 2021, 152: 21-26.
9 Han YB, Kim H, Mino-Kenudson M, et al. Tumor spread through air spaces(STAS): prognostic significance of grading in non-small cell lung cancer[J]. Mod Pathol, 2021, 34(3): 549-561.
10 Vaghjiani RG, Takahashi Y, Eguchi T, et al. Tumor spread through air spaces is a predictor of occult lymph node metastasis in clinical stage ⅠA lung adenocarcinoma[J]. J Thorac Oncol, 2020, 15(5): 792-802.
11 Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.[J]. N Engl JMed, 2010, 362(25): 2380-2388.
12 Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
13 Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): v192-v237.
14 Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy[J]. Ann Oncol, 2021, 32(12): 1637-1642.
15 沈 晨, 方文涛. ⅠA期肺腺癌病理高危因素及术后辅助化疗研究进展[J]. 中国肺癌杂志, 2022, 25(8): 593-600.
16 Yun JK, Lee GD, Choi S, et al. Various recurrence dynamics for non-small cell lung cancer depending on pathological stage and histology after surgical resection[J]. Transl Lung Cancer Res, 2022, 11(7): 1327-1336.
17 Ito M, Miyata Y, Kushitani K, et al. Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma[J]. Thorac Cancer, 2018, 9(12): 1594-1602.
18 He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage Ⅱ-ⅢA EGFR-mutant non-small-cell lung cancer(EVIDENCE): a randomised, open-label, phase 3 trial[J]. Lancet Respir Med, 2021, 9(9): 1021-1029.
19 Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage ⅢA EGFR mutation-positive non-small-cell lung cancer(EVAN): a randomised, open-label, phase 2 trial[J]. Lancet Respir Med, 2018, 6(11): 863-873.
20 Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA(N1-N2)EGFR-mutant NSCLC(ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2018, 19(1): 139-148.
21 Tsuboi M, Wu Y, Grohe C, et al. LBA47 Osimertinib as adjuvant therapy in patients(pts)with resected EGFR-mutated(EGFRm)stage ⅠB-ⅢIA non-small cell lung cancer(NSCLC): Updated results from ADAURA[J]. Ann Oncol, 2022, 33: S1413-S1414.
22 Saw SPL, Lai G, Zhou S, et al. OA06.05 Molecular and clinical features associated with relapse in early stage EGFR-Mutated NSCLC: A single institution knowledge bank[J]. J Thoracic Oncol, 2021, 16(3, Supplement): S114-S115.
23 Garinet S, Wang P, Mansuet-Lupo A, et al. Updated prognostic factors in localized NSCLC[J]. Cancers(Basel), 2022, 14(6): 1400.
24 Masago K, Kuroda H, Fujita S, et al. Biological difference between L858R and exon 19 deletion contributes to recurrence-free survival of resected non-small cell lung cancer[J]. Oncology, 2022, doi: 10.1159/000526973.
25 Hedley BD, Chambers AF. Tumor dormancy and metastasis[J]. Adv Cancer Res, 2009, 102: 67-101.
26 Hung JJ, Jeng WJ, Hsu WH, et al. Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis[J]. Thorax, 2010, 65(3): 241-245.
27 Moreira AL, Ocampo P, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: A proposal from the international association for the study of lung cancer pathology committee[J]. J Thorac Oncol, 2020, 15(10): 1599-1610.
28 Nicholson AG, Tsao MS, Beasley MB, et al. The 2021 WHO classification of lung tumors: Impact of advances since 2015[J]. J Thorac Oncol, 2022, 17(3): 362-387.
29 Kim M, Chung YS, Kim KA, et al. Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung[J]. Lung Cancer, 2019, 137: 129-135.
30 Lin C, Hu F, Chu H, et al. The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis[J]. Thorac Cancer, 2021, 12(7): 1084-1095.
31 Tada H, Mitsudomi T, Misumi T, et al. Randomized phase Ⅲ study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage Ⅱ-ⅢA non-small-cell lung cancer with EGFR mutation(IMPACT)[J]. J Clin Oncol, 2022, 40(3): 231-241.
32 蒋仲敏, 林殿杰, 叶 莘, 等. 循环肿瘤细胞、循环染色体异常细胞与肺癌早期诊断[J]. 精准医学杂志, 2020, 35(2): 95-99.

备注/Memo

备注/Memo:

基金项目: 重庆市卫生适宜技术推广项目(2020jstg016)
通信作者: 周向东, Email: xiangdongzhou@126.com

常用功能

更新日期/Last Update: 2022-12-20